{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:49:21Z","timestamp":1762876161614,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.arteri.2020.02.003","type":"journal-article","created":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T16:59:01Z","timestamp":1587229141000},"page":"183-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Perfil cl\u00ednico de los pacientes tratados con evolocumab en unidades de l\u00edpidos\/medicina interna en Espa\u00f1a. Estudio observacional (RETOSS-IMU)"],"prefix":"10.1016","volume":"32","author":[{"given":"Llu\u00eds","family":"Masana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"L\u00f3pez Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Civeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Reinares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Guijarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Plana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Cuenca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demetrio","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimundo","family":"Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agust\u00edn","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Villamayor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2020.02.003_bib0120","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2020.02.003_bib0125","unstructured":"Instituto Nacional de Estad\u00edstica. Defunciones seg\u00fan la causa de muerte, 2016 [consultado 8 Abr 2019]. Disponible en: http:\/\/www.ine.es\/jaxi\/Tabla.htm?path=\/t15\/p417\/a2016\/l0\/&file=01003.px&L=0.8"},{"key":"10.1016\/j.arteri.2020.02.003_bib0130","unstructured":"European Heart Network. CVD Statistics [consultado 28 May 2019]. Disponible en: http:\/\/www.ehnheart.org\/cvd-statistics.html"},{"key":"10.1016\/j.arteri.2020.02.003_bib0135","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.recesp.2013.05.014","article-title":"Contribuciones de la mortalidad cardiovascular a la esperanza de vida de la poblaci\u00f3n espa\u00f1ola de 1980 a 2009","volume":"66","author":"Garc\u00eda-Gonz\u00e1lez","year":"2013","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.arteri.2020.02.003_bib0140","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jama.1997.03550040069040","article-title":"Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials","volume":"278","author":"Hebert","year":"1997","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2020.02.003_bib0145","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2020.02.003_bib0150","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2020.02.003_bib0155","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2020.02.003_bib0160","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2020.02.003_bib0165","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2020.02.003_bib0170","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: A prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2020.02.003_bib0175","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1177\/2047487318825350","article-title":"Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry","volume":"26","author":"Kotseva","year":"2019","journal-title":"Eur J Prev Cardiol."},{"key":"10.1016\/j.arteri.2020.02.003_bib0180","first-page":"155","article-title":"Consecuci\u00f3n del objetivo terap\u00e9utico del colesterol de las lipoprote\u00ednas de baja densidad en las unidades de l\u00edpidos y riesgo vascular de la Sociedad Espa\u00f1ola de Arteriosclerosis","volume":"25","author":"Pedro-Botet","year":"2013","journal-title":"Clin Investig Arterioscler."},{"key":"10.1016\/j.arteri.2020.02.003_bib0185","first-page":"164","article-title":"Documento de consenso de la Sociedad Espa\u00f1ola de Arteriosclerosis sobre las indicaciones de los inhibidores de la PCSK9","volume":"28","author":"Masana","year":"2016","journal-title":"Clin Investig Arterioscl."},{"key":"10.1016\/j.arteri.2020.02.003_bib0190","first-page":"128","article-title":"Indicaciones de los inhibidores de PCSK9 en la pr\u00e1ctica cl\u00ednica. Recomendaciones de la Sociedad Espa\u00f1ola de Arteriosclerosis (SEA), 2019","volume":"31","author":"Ascaso","year":"2019","journal-title":"Clin Investig Arterioscl."},{"key":"10.1016\/j.arteri.2020.02.003_bib0195","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terap\u00e9utico de evolocumab (Repatha\u00ae) en hipercolesterolemia, 2016 [consultado 19 Abr 2019]. Disponible en: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-evolocumab-repatha.pdf"},{"key":"10.1016\/j.arteri.2020.02.003_bib0200","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terap\u00e9utico de alirocumab (Praluent\u00ae) en hipercolesterolemia, 2016 [consultado 19 Abr 2019]. Disponible en: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-alirocumab-Praluent-hipercolesterolemia.pdf"},{"key":"10.1016\/j.arteri.2020.02.003_bib0205","unstructured":"European Medicines Agency. EMA\/233126\/2018. Committee for Medicinal Products for Human Use (CHMP). Assessment report: Repatha, 2018 [consultado 19 Abr 2019]. Disponible en: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/repatha-h-c-3766-ii-0017-g-epar-assessment-report-variation_en.pdf"},{"key":"10.1016\/j.arteri.2020.02.003_bib0210","unstructured":"European Medicines Agency. EMA\/CHMP\/44606\/2019. Committee for Medicinal Products for Human Use (CHMP). Summary of opinion (post authorisation): Praluent (alirocumab), 2019 [consultado 19 Abr 2019]. Disponible en: https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-praluent-ii-42_en.pdf"},{"key":"10.1016\/j.arteri.2020.02.003_bib0215","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2020.02.003_bib0220","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2020.02.003_bib0225","doi-asserted-by":"crossref","unstructured":"Barrios V. Escobar C. Arrarte V. Rold\u00e1n C. Primer registro nacional de evolocumab en la pr\u00e1ctica cl\u00ednica en unidades de cardiolog\u00eda en Espa\u00f1a. Estudio RETOSS-CARDIO. Rev Esp Cardiol. Disponible online el 7 Ene 2020 en: http:\/\/www.revespcardiol.org\/es-primer-registro-nacional-evolocumab-practica-avance-S0300893219305536","DOI":"10.1016\/j.recesp.2019.11.014"},{"key":"10.1016\/j.arteri.2020.02.003_bib0230","unstructured":"Experiencia inicial en la pr\u00e1ctica cl\u00ednica con los inhibidores PCSK\u20139 para las indicaciones actuales de financiaci\u00f3n en Espa\u00f1a. Rev Esp Cardiol. [consultado 7 Feb 2020]. Disponible en: https:\/\/www.revespcardiol.org\/es-experiencia-inicial-practica-clinica-con-articulo-S0300893219301629?"}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916820300243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916820300243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:32:16Z","timestamp":1759325536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916820300243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0214916820300243"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2020.02.003","relation":{},"ISSN":["0214-9168"],"issn-type":[{"type":"print","value":"0214-9168"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perfil cl\u00ednico de los pacientes tratados con evolocumab en unidades de l\u00edpidos\/medicina interna en Espa\u00f1a. Estudio observacional (RETOSS-IMU)","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2020.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Arteriosclerosis.","name":"copyright","label":"Copyright"}]}}